Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluocinolone Acetonide

            Therapeutic Area: Ophthalmology Product Name: Iluvien

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2021

            Details:

            ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loteprednol Etabonate

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2021

            Details:

            Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Netarsudil Mesylate,Latanoprost

            Therapeutic Area: Ophthalmology Product Name: Roclanda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 11, 2021

            Details:

            European Commission has granted a marketing authorisation for Roclanda® 0.02%/0.005% for high intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil are insufficient for IOP reduction.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluocinolone Acetonide

            Therapeutic Area: Ophthalmology Product Name: Yutiq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: OcuMension Therapeutics

            Deal Size: $15.7 million Upfront Cash: Undisclosed

            Deal Type: Financing January 03, 2021

            Details:

            This investment underscores eyepoints' continued strong partnership with Ocumension for YUTIQ and DEXYCU in Asia. The companies in collaboration, are conducting Phase 1 trial of EYP-1901 in wet age-related macular degeneration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluocinolone Acetonide

            Therapeutic Area: Ophthalmology Product Name: Iluvien

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: SWK Holdings Corporation

            Deal Size: $16.5 million Upfront Cash: Undisclosed

            Deal Type: Agreement December 18, 2020

            Details:

            The transaction with SWK allows EyePoint to reduce existing debt and interest obligations and improve its balance sheet in advancing its ocular disease pipeline, including EYP-1901 for wet age-related macular degeneration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluocinolone Acetonide

            Therapeutic Area: Ophthalmology Product Name: Yutiq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            Second Ph3 trial of YUTIQ confirms 36-month positive efficacy results from the first Ph3 trial. Study of DEXYCU vs. Prednisolone eye drops shows high patient preference for DEXYCU with statistically better inflammation control, pain, visual acuity outcomes in DEXYCU group.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Netarsudil Mesylate,Latanoprost

            Therapeutic Area: Ophthalmology Product Name: Roclanda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: Dextenza

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: AffaMed Therapeutics

            Deal Size: $103.0 million Upfront Cash: $12.0 million

            Deal Type: Licensing Agreement October 30, 2020

            Details:

            AffaMed has received rights to develop and market DEXTENZA to reduce post-surgical inflammation and pain and ocular itching in patients with allergic conjunctivitis, and OTX-TIC t reduce high intraocular pressure in ocular hypertension in Greater China, South Korea and Asia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Netarsudil

            Therapeutic Area: Ophthalmology Product Name: Rhopressa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Santen Pharmaceutical

            Deal Size: $149.0 million Upfront Cash: $50.0 million

            Deal Type: Licensing Agreement October 28, 2020

            Details:

            Santen will look after sales, marketing and pricing decisions relating to Rhopressa® and Rocklatan®. Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa® in Japan.